In vitro synergy of 5-nitrofurans, vancomycin and sodium deoxycholate against Gram-negative pathogens. Issue 3 (15th March 2021)

• Record Type: Journal Article
• Authors: Olivera, Catrina; Le, Vuong Van Hung; Davenport, Catherine; Rakonjac, Jasna
• Is Part Of: Journal of medical microbiology. Volume 70:Issue 3(2021)
• Publication Date: 2021-03-15
• Subjects: antibiotic resistance -- enterobacteria -- nitrofurans -- sodium deoxycholate -- synergy -- vancomycin; Medical microbiology -- Periodicals; 616.9041
• DOI: 10.1099/jmm.0.001304
• Languages: English
• ISSNs: 0022-2615

Abstract

Abstract : Introduction. There is an urgent need for effective therapies against bacterial infections, especially those caused by antibiotic-resistant Gram-negative pathogens. Hypothesis. Synergistic combinations of existing antimicrobials show promise due to their enhanced efficacies and reduced dosages which can mitigate adverse effects, and therefore can be used as potential antibacterial therapy. Aim. In this study, we sought to characterize the in vitro interaction of 5-nitrofurans, vancomycin and sodium deoxycholate (NVD) against pathogenic bacteria. Methodology. The synergy of the NVD combination was investigated in terms of growth inhibition and bacterial killing using checkerboard and time-kill assays, respectively. Results. Using a three-dimensional checkerboard assay, we showed that 5-nitrofurans, sodium deoxycholate and vancomycin interact synergistically in the growth inhibition of 15 out of 20 Gram-negative strains tested, including clinically significant pathogens such as carbapenemase-producing Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii, and interact indifferently against the Gram-positive strains tested. The time-kill assay further confirmed that the triple combination was bactericidal in a synergistic manner. Conclusion. This study demonstrates the synergistic effect of 5-nitrofurans, sodium deoxycholate and vancomycin against Gram-negative pathogens and highlights the potential of the combination as a treatment for Gram-negative and Gram-positive infections.